Dianthus Therapeutics (DNTH) TD Cowen 46th Annual Health Care Conference summary

Key program updates and milestones

• Phase II data for claseprubart in MG showed strong efficacy and safety, boosting confidence in the drug's potential as a neuromuscular therapeutic.

• The pivotal phase III CIDP trial is designed as a switch study, with interim responder analysis expected in Q2, focusing on efficacy above standard care and rapid patient recruitment.

• MMN phase II top-line results are anticipated in the second half of the year, with the study closely mirroring successful precedents and aiming for rapid progression to phase III.

• Recruitment for the CIDP trial is accelerating, attributed to patient-friendly design and positive investigator feedback, contrasting with delays in competing studies.

• External catalysts include upcoming phase III data from competitors, which may influence future head-to-head studies and market positioning.

Clinical trial design and competitive differentiation

• The CIDP trial allows refractory patients and immediate switch from IVIG, differentiating it from prior studies that required washout and relapse.

• Only patients who improve beyond their baseline on IVIG are randomized, aiming to demonstrate efficacy superior to standard care.

• The trial's structure enables potential reduction in sample size and faster market entry if efficacy targets are met, with strong signals expected if the higher dose arm is dropped.

• MMN study design closely replicates successful competitor protocols but is smaller and faster, focusing on safety and efficacy to expedite development.

• Differentiation is expected through dosing convenience (subcutaneous vs. IV), safety profile, and potentially avoiding certain regulatory warnings.

Safety considerations and regulatory perspectives

• Theoretical risk of drug-induced lupus-like symptoms (DILS) is addressed, with no cases observed in C1s inhibitor programs to date; monitoring is routine but expected to be discontinued after phase II.

• C1q inhibitors have shown DILS due to their dual function, but C1s inhibitors target only the complement cascade, reducing this risk.

• Regulatory discussions have been positive, with trial design aligned to precedents set by recent FDA approvals in the space.

• Ongoing studies include monitoring for autoimmune activation, with plans to expand investigator-led research on mechanistic questions.

• Safety and tolerability remain a focus, especially as new data from competitors become available.